Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shumei Kato

Showing results (1-10 of 168) with videos related to

Pageof 17
Sort By:
Nature Biotechnology|November 10, 2018
An avatar for precision cancer therapyShumei Kato, Razelle Kurzrock
Journal of Immunotherapy and Precision Oncology|June 25, 2021
Repurposing Interleukin-6 Inhibitors to Combat COVID-19Shumei Kato, Razelle Kurzrock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2017
Genomics of Immunotherapy-Associated Hyperprogressors-ResponseShumei Kato, Razelle Kurzrock
Biomarkers in Medicine|July 16, 2015
Cell-free DNA as a novel marker in cancer therapyShumei Kato, Filip Janku
Oncology (Williston Park, N.Y.)|April 24, 2018
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseRazelle Kurzrock, Shumei Kato
Journal of Immunotherapy and Precision Oncology|August 2, 2021
The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer CentersDiviya Gupta, Shumei Kato, Razelle Kurzrock
Journal of Hematology & Oncology|September 12, 2022
Liquid biopsy: current technology and clinical applicationsMina Nikanjam, Shumei Kato, Razelle Kurzrock
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take CreditShumei Kato, Vivek Subbiah, Razelle Kurzrock
European Journal of Cancer (Oxford, England : 1990)|August 26, 2020
Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation"Jason Sicklick, Shumei Kato, Razelle Kurzrock
Journal of Immunotherapy and Precision Oncology|December 9, 2022
Of Mice, Not Men: When the Bench-to-Bedside Bridge Is BrokenMina Nikanjam, Shumei Kato, Razelle Kurzrock
Pageof 17

Showing results (1-10 of 168) with videos related to

Sort By:
Pageof 17
Nature Biotechnology|November 10, 2018
An avatar for precision cancer therapyShumei Kato, Razelle Kurzrock
Journal of Immunotherapy and Precision Oncology|June 25, 2021
Repurposing Interleukin-6 Inhibitors to Combat COVID-19Shumei Kato, Razelle Kurzrock
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2017
Genomics of Immunotherapy-Associated Hyperprogressors-ResponseShumei Kato, Razelle Kurzrock
Biomarkers in Medicine|July 16, 2015
Cell-free DNA as a novel marker in cancer therapyShumei Kato, Filip Janku
Oncology (Williston Park, N.Y.)|April 24, 2018
Razelle Kurzrock and Shumei Kato on Immunotherapy and Hyperprogression of DiseaseRazelle Kurzrock, Shumei Kato
Journal of Immunotherapy and Precision Oncology|August 2, 2021
The Impact of COVID-19 on Cancer Clinical Trials Conducted by NCI-Designated Comprehensive Cancer CentersDiviya Gupta, Shumei Kato, Razelle Kurzrock
Journal of Hematology & Oncology|September 12, 2022
Liquid biopsy: current technology and clinical applicationsMina Nikanjam, Shumei Kato, Razelle Kurzrock
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take CreditShumei Kato, Vivek Subbiah, Razelle Kurzrock
European Journal of Cancer (Oxford, England : 1990)|August 26, 2020
Letter responds to comment on "intention-to-treat analysis in precision oncology: A cautious interpretation"Jason Sicklick, Shumei Kato, Razelle Kurzrock
Journal of Immunotherapy and Precision Oncology|December 9, 2022
Of Mice, Not Men: When the Bench-to-Bedside Bridge Is BrokenMina Nikanjam, Shumei Kato, Razelle Kurzrock
Pageof 17